Cost-effectiveness analysis of tislelizumab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China-Reference-Cited by-同舟云学术

Cost-effectiveness analysis of tislelizumab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China

Published:2024-09-14 Issue: Volume: Page:
ISSN:2210-7703
Container-title:International Journal of Clinical Pharmacy
language:en
Short-container-title:Int J Clin Pharm

Author:

Lang Wenwang^ORCID,Ai Qi,He Yulong,Pan Yufei,Jiang Qinling,Ouyang Ming,Sun Tianshou

Funder

Drug clinical comprehensive evaluation project of Health Commission of Guangxi Zhuang Autonomous Region

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s11096-024-01802-1.pdf

Reference40 articles.

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.

2. Oronsky B, Abrouk N, Caroen S, et al. A 2022 update on extensive stage small-cell lung cancer (SCLC). J Cancer. 2022;13(9):2945–53. https://doi.org/10.7150/jca.75622.

3. Rudin CM, Brambilla E, Faivre-Finn C, et al. Small-cell lung cancer. Nat Rev Dis Primers. 2021;7(1):3. https://doi.org/10.1038/s41572-020-00235-0.

4. Sathiyapalan A, Febbraro M, Pond GR, et al. Chemo-immunotherapy in first line extensive stage small cell lung Cancer (ES-SCLC): a systematic review and meta-analysis. Curr Oncol. 2022;29(12):9046–65. https://doi.org/10.3390/curroncol29120709.

5. Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929–39. https://doi.org/10.1016/s0140-6736(19)32222-6.